The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
Apixaban Length-Of-Stay Pulmonary Embolism Study - Hospital Admissions (ALPHA-PE)
Sponsor: Bristol-Myers Squibb
A observational or N/A phase clinical study on Pulmonary Embolism (PE) and Pulmonary Thromboembolism, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jun 2022 — Jul 2024 [monthly]
Completed
Status: Unknown Status → Completed
-
Jan 2021 — Jun 2022 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jan 2019 — Jan 2021 [monthly]
Active Not Recruiting
▶ Show 2 earlier versions
-
Nov 2018 — Jan 2019 [monthly]
Active Not Recruiting
-
Aug 2018 — Nov 2018 [monthly]
Active Not Recruiting
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .